Home
Search:
1146 feeds
357 categories
4224 articles (<24 hours)
20 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

Science


Valid HTML 4.01 Transitional

RSS FeedsViracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting
(WorldNews Health)

 
 

8 december 2019 19:00:06

 
Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting
(WorldNews Health)
 




SAN DIEGO, Dec. 8, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. (the `Company`), a precision oncology company targeting virus-associated malignancies, announced today that its lead investigator, Dr. Pierluigi Porcu of the Sidney Kimmel Cancer Center, Thomas Jefferson University, presented new clinical data from the Company`s Phase 1b/2a clinical trial of the orally administered combination of nanatinostat (Nstat) in combination with the antiviral valganciclovir for the treatment of EBV-associated relapsed/refractory lymphomas. The data were presented during an oral presentation at the ASH Annual Meeting in Orlando, Florida. The Phase 1b/2a clinical study [NCT03397706] evaluated the...
 
55 viewsCategory: Science > Medicine
 
Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies
(WorldNews Health)
Do I Have an Eating Disorder?
(WorldNews Health)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2020 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Travel Photos Nachrichten Indigonet Finances Leer Mandarijn